V Wealth Advisors LLC trimmed its holdings in Colgate-Palmolive (NYSE:CL) by 6.5% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 3,857 shares of the company’s stock after selling 266 shares during the quarter. V Wealth Advisors LLC’s holdings in Colgate-Palmolive were worth $233,000 at the end of the most recent quarter.
Other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. raised its stake in Colgate-Palmolive by 1.0% in the 3rd quarter. Vanguard Group Inc. now owns 73,520,894 shares of the company’s stock valued at $4,922,224,000 after acquiring an additional 734,860 shares during the period. Vanguard Group Inc grew its holdings in shares of Colgate-Palmolive by 1.0% during the 3rd quarter. Vanguard Group Inc now owns 73,520,894 shares of the company’s stock worth $4,922,224,000 after purchasing an additional 734,860 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in Colgate-Palmolive by 1.1% in the third quarter. Bank of New York Mellon Corp now owns 20,359,199 shares of the company’s stock valued at $1,363,050,000 after buying an additional 223,814 shares in the last quarter. Morgan Stanley boosted its stake in Colgate-Palmolive by 15.0% in the third quarter. Morgan Stanley now owns 7,212,524 shares of the company’s stock valued at $482,879,000 after buying an additional 941,008 shares in the last quarter. Finally, Franklin Resources Inc. boosted its stake in Colgate-Palmolive by 0.8% in the third quarter. Franklin Resources Inc. now owns 4,790,397 shares of the company’s stock valued at $320,717,000 after buying an additional 37,145 shares in the last quarter. 74.62% of the stock is owned by institutional investors and hedge funds.
In related news, Director John T. Cahill sold 5,780 shares of the business’s stock in a transaction dated Thursday, January 31st. The stock was sold at an average price of $64.46, for a total transaction of $372,578.80. Following the completion of the transaction, the director now directly owns 27,820 shares in the company, valued at $1,793,277.20. The transaction was disclosed in a document filed with the SEC, which is available through this link. 1.02% of the stock is owned by insiders.
Shares of CL opened at $65.69 on Monday. The firm has a market capitalization of $56.97 billion, a price-to-earnings ratio of 22.12, a PEG ratio of 4.24 and a beta of 0.78. Colgate-Palmolive has a 1 year low of $57.41 and a 1 year high of $72.61.
Colgate-Palmolive (NYSE:CL) last issued its earnings results on Friday, January 25th. The company reported $0.74 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.73 by $0.01. Colgate-Palmolive had a return on equity of 25,268.29% and a net margin of 15.44%. The firm had revenue of $3.81 billion for the quarter, compared to analyst estimates of $3.78 billion. During the same period in the previous year, the company posted $0.75 earnings per share. The business’s revenue was down 2.1% on a year-over-year basis. On average, equities research analysts predict that Colgate-Palmolive will post 2.83 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, February 15th. Investors of record on Wednesday, January 23rd will be given a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a yield of 2.56%. The ex-dividend date is Tuesday, January 22nd. Colgate-Palmolive’s payout ratio is 56.57%.
Several analysts recently weighed in on CL shares. Goldman Sachs Group raised Colgate-Palmolive from a “neutral” rating to a “buy” rating in a research note on Tuesday, January 8th. Zacks Investment Research downgraded Colgate-Palmolive from a “hold” rating to a “strong sell” rating in a research report on Wednesday, January 30th. Jefferies Financial Group reiterated a “hold” rating and issued a $61.00 target price on shares of Colgate-Palmolive in a research report on Friday, February 1st. Morgan Stanley lowered their target price on Colgate-Palmolive from $65.00 to $60.00 and set a “hold” rating for the company in a report on Tuesday, October 30th. Finally, JPMorgan Chase & Co. downgraded Colgate-Palmolive from a “neutral” rating to an “underweight” rating and lowered their target price for the stock from $61.00 to $54.00 in a report on Monday, October 29th. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating and four have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $65.00.
TRADEMARK VIOLATION WARNING: This news story was originally posted by Fairfield Current and is the property of of Fairfield Current. If you are viewing this news story on another website, it was copied illegally and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.fairfieldcurrent.com/news/2019/02/11/v-wealth-advisors-llc-has-233000-holdings-in-colgate-palmolive-cl.html.
Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. It operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. The company offers oral care products, including toothpastes, toothbrushes, and mouthwashes, as well as pharmaceutical products for dentists and other oral health professionals; personal care products comprising bar and liquid hand soaps, shower gels, shampoos, conditioners, and deodorants and antiperspirants; and home care products, such as laundry and dishwashing detergents, fabric conditioners, household cleaners, and other related products.
Further Reading: What is the quiet period?
Receive News & Ratings for Colgate-Palmolive Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Colgate-Palmolive and related companies with MarketBeat.com’s FREE daily email newsletter.